Baystreet Staff -

Skinvisible's Kintari Revolutionizes the Sunscreen Market Skinbrella(R) Officially Launched


LAS VEGAS, NV / ACCESSWIRE / April 17, 2015 / Skinvisible Inc., (OTCQB: SKVI) through its wholly-owned subsidiary Kintari International Inc., marketer of patented "Youth Renewed" skin care products, is pleased to announce the official launch of Skinbrella(R), a patented sunscreen like no other. Skinbrella meets or exceeds all FDA requirements for a broad-spectrum, 80 minute water-resistant sunscreen.

"With millions of new skin cancer diagnosis each year, sun protection should be a daily lifestyle choice for everyone," said Mr. Terry Howlett, President of Kintari. "The challenge of course is many sunscreens breakdown when exposed to sunlight or esthetically they are not pleasing. Kintari provides a solution to everyone's daily sunscreen needs with Skinbrella. Today we are thrilled to announce that Skinbrella; a truly remarkable sunscreen with the patents to prove it, is available on and through our independent distributors and their websites."

Skinbrella is a broad spectrum, SPF 30 sunscreen made with the Company's patented topical delivery technology Invisicare(R). It provides 80 minutes of water resistance; the highest designation allowed by the FDA. Skinbrella glides on smoothly without any sticky after feel, while still allowing the skin to breath naturally. It meets the requirements to be labeled "broad spectrum", signifying it provides both UVA and UVB protection.

Avobenzone, the only UVA absorber approved by the FDA, degrades in the sun in less than two hours resulting in less skin protection. Skinbrella conversely has proven to deliver eight hours of photostability of avobenzone, a unique advantage for which a patent was granted by the United States Patent and Trademark Office. The patent: "Sunscreen Composition With Enhanced UVA Absorber Stability and Methods", Patent Number 8128913 proves the ability of Invisicare to stabilize avobenzone, one of the essential benefits of Skinbrella. The FDA sunscreen monograph recommends the re-application of sunscreen every 2 hours for maximum protection. Skinbrella's labeling follows this recommendation.

Kintari launched in January as a direct sales company and has seen increased growth both in revenue and distributors every month for its first quarter. Kintari's keystone products include its Youth Renewed Day and Night creams. These anti-aging products provide exceptional anti-aging solutions, all powered by our patented Invisicare(R) technology. With the addition of Skinbrella broad spectrum sunscreen, Kintari will continue its brand expansion across the United States driven by the exceptional distributors representing Kintari products.

Skinvisible Inc., is a science-based research and development company with a patented skin delivery technology Invisicare(R), the foundation to every topical prescription (Rx), over-the-counter (OTC) and cosmeceutical product developed by Skinvisible. Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription line of dermatology focused products, while its wholly-owned subsidiary Kintari focuses exclusively on the marketing of OTC and cosmeceutical products. The Company has over fifteen patents worldwide and a portfolio of over forty products ready to be licensed or introduced to the marketplace.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. In addition, Skinvisible's wholly-owned subsidiary Kintari will commercialize its cosmeceutical and OTC product line globally through network marketing.,,

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the year ending December 31st, 2014).

Corporate Contact:

Doreen McMorran
Skinvisible Inc. & Kintari USA Inc.
Email: [email protected]


SOURCE: Skinvisible Inc.